Trial Profile
CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Sep 2016
Price :
$35
*
At a glance
- Drugs Latrepirdine (Primary)
- Indications Alzheimer's disease
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms CONTACT
- 26 Sep 2012 Waiting for a couple of endpoints to be added to Thes
- 31 Aug 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 10 May 2010 Status changed from recruiting to suspended, according to a Medivation media release.